3 results about "Postoperative treatment" patented technology

The present application relates to the field of biological medicine, and particularly relates to a kind of nanocomposite and its preparation method and application in postoperative treatment of pancreatic cancer.The nanocomposite is that RRM2 siRNA is compounded with gold nanocluster AuNCs, then is loaded into mesenchymal stem cell-derived exosome MSC-EVs, and the nanocomposite AuNC-siRNA / EV is prepared.The present application can generate nanocomposite with high drug loading efficiency and lysosome escape ability by electrostatic self-assembly of gold nanoparticles and siRNA and membrane fusion technology of MSC-EVs.RRM2 siRNA can be accurately delivered to residual tumor lesions using the natural homing characteristics of MSC-EVs, thereby inhibiting RRM2 expression, blocking DNA synthesis and stem cell characteristics of tumor cells, and further inhibiting micro-metastasis proliferation and immune escape, which opens up a new paradigm for postoperative treatment of pancreatic cancer.

This invention discloses a sustained-release membrane for postoperative treatment of diabetic peripheral neuropathy and its preparation method. The sustained-release membrane comprises, from the outside in, a PLGA nanofiber outer layer containing tacrolimus and magnesium hydroxide nanoparticles, a glucose-responsive hydrogel middle layer containing insulin and glucose oxidase / catalase, and a PCL-oriented nanofiber inner layer containing methylcobalamin. The layers are connected by a polydopamine interface layer, and the outermost surface of the outer layer is coated with a hyaluronic acid anti-adhesion coating. Insulin, as a local neurotrophic factor, directly activates the PI3K / Akt / mTOR and ERK / MAPK signaling pathways, promoting axonal regeneration and myelin repair. The sustained-release membrane integrates three major functions: immunomodulation / anti-inflammation, glucose-responsive insulin neurotrophic delivery, and sustained nerve regeneration promotion. It prevents postoperative nerve re-adhesion through a spatiotemporal sequential drug release strategy. All components are biodegradable and do not require secondary surgery for removal.

The invention relates to a nasal conformer (20) comprising: two nasal cannulas (40) respectively configured for insertion into the patient's nostrils, and a facial flange (30) comprising: two openings (31) junctioning the facial flange (30) and the two nasal cannulas (40) extending behind the facial flange (30), a midsection (32) configured to cover the patient's columella, the midsection (32) being disposed between the two openings (31). According to the invention, each nasal cannula (40) has a boss (44) configured to bear against the soft triangle of the patient's nostril. [Figure for the abstract: Fig. 7]